Osteoporosis Drugs Market Analysis By Product (Branded, Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM), Rank Ligand Inhibitors, Generics), And Segment Forecasts, 2014 - 2025

  • ID: 4076530
  • Report
  • 78 pages
  • Grand View Research
1 of 4

FEATURED COMPANIES

  • Allergan plc
  • Amgen, Inc.
  • Eli Lilly and Company
  • F.Hoffmann La Roche
  • GlaxoSmithKline
  • Merck & Co AG
  • MORE
The global osteoporosis drugs market is expected to reach USD 16.3 billion by 2025. An upsurge rise in the unhealthy lifestyle adoption has resulted in aggravation and increase in the prevalence of osteoporosis which is presumed to propel the osteoporosis drugs market during the forecast period.

In addition, growing number of patent expiries is fueling the high clinical urgency to use generic versions of the established drugs, which is presumed to fuel generic osteoporosis drugs market during the forecast period. The aforementioned factors cumulatively are slated to present the with high potential growth opportunities over the coming years.

Furthermore, rising number of initiatives to increase the awareness levels pertaining to osteoporosis care amongst the patients as well as the physicians is expected to widen the osteoporosis market growth potential during the forecast period. For instance, National Osteoporosis Foundation (NOF), a healthcare organization responsible for National Bone Health Alliance and Fracture Liaison Service (FLS) care coordination programs that focuses on elevating awareness levels as well as provides training to healthcare professionals

Further key findings from the study suggest:

Branded drugs held the dominant share of the product segment in 2015. The dominant share can be attributed to extensive utilization of bisphosphates, rank ligand inhibitors for the treatment of osteoporosis, possessing high efficacy

Generics are expected to witness at a lucrative CAGR owing to consistent patent expiries over the coming years as well as high clinical urgency for inexpensive medication in the emerging economies

In 2015, North America accounted for the largest share in the global osteoporosis drugs market owing to the presence of established companies extensively involved in the commercialization of branded therapeutics

Asia Pacific is anticipated to grow at an exponential CAGR as a consequence of favorable government initiatives promoting information pertaining to osteoporosis care

The key participants are employing sustainability strategies promoting the adoption of osteoporosis therapeutics to gain competitive advantage. For instance, Actavis Inc. announced to acquire Warner Chilcott PLC in order to widen their product portfolio
PLEASE NOTE: This report will be completed after order and will take approximately 1-2 business days after the confirmation of payment.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Allergan plc
  • Amgen, Inc.
  • Eli Lilly and Company
  • F.Hoffmann La Roche
  • GlaxoSmithKline
  • Merck & Co AG
  • MORE
1 Research Methodology & Scope
1.1 Region Wise Market Calculation
1.1.1 Region Wise Market: Base Estimates
1.1.2 Global Market: CAGR Calculation
1.2 Region based segment share calculation
1.3 List of Secondary Sources

2 Executive Summary
2.1 Market summary

3 Osteoporosis Drugs Market Variables, Trends & Scope
3.1 Market segmentation& scope
3.1.1 Market Driver Analysis
3.1.2 Market Restraint Analysis
3.2 Penetration & Growth Prospect Mapping
3.3 Osteoporosis Drugs - SWOT Analysis
3.4 Industry Analysis - Porter’s
3.5 Product Pipeline Analysis
3.6 Company Market Share, 2015

4 Osteoporosis Drugs Product Estimates & Trend Analysis
4.1 Osteoporosis Drugs Market: Product Movement Analysis
4.2 Branded
4.2.1 Branded market, 2014 - 2025 (USD Million)
4.2.2 Bisphosphonates
4.2.2.1 Bisphosphonates market, 2014 - 2025 (USD Million)
4.2.3 Parathyroid Hormone Therapy
4.2.3.1 Parathyroid hormone therapy market, 2014 - 2025 (USD Million)
4.2.4 Calcitonin
4.2.4.1 Calcitonin market, 2014 - 2025 (USD Million)
4.2.5 Selective Estrogen Inhibitors Modulator (SERM)
4.2.5.1 SERM market, 2014 - 2025 (USD Million)
4.2.6 Rank Ligand Inhibitors
4.2.6.1 Rank ligand Inhibitors market, 2014 - 2025 (USD Million)
4.2.7 Others
4.2.7.1 Others market, 2014 - 2025 (USD Million)
4.3 Generic
4.3.1 Generic market, 2014 - 2025 (USD Million)

5 Osteoporosis Drugs Regional Estimates & Trend Analysis, by Product
5.1 Osteoporosis drugs market share by region, 2015 & 2025
5.2 North America
5.2.1 North America osteoporosis drugs market, 2014 - 2025 (USD Million)
5.2.2 U.S.
5.2.2.1 U.S. osteoporosis drugs market, 2014 - 2025 (USD Million)
5.2.3 Canada
5.2.3.1 Canada osteoporosis drugs market, 2014 - 2025 (USD Million)
5.3 Europe
5.3.1 Europe osteoporosis drugs market, 2014 - 2025 (USD Million)
5.3.2 UK
5.3.2.1 UK osteoporosis drugs market, 2014 - 2025 (USD Million)
5.3.3 Germany
5.3.3.1 Germany osteoporosis drugs market, 2014 - 2025 (USD Million)
5.4 Asia Pacific
5.4.1 Asia Pacific osteoporosis drugs market, 2014 - 2025 (USD Million)
5.4.2 Japan
5.4.2.1 Japan osteoporosis drugs market, 2014 - 2025 (USD Million)
5.4.3 China
5.4.3.1 China osteoporosis drugs market, 2014 - 2025 (USD Million)
5.4.4 India
5.4.4.1 India osteoporosis drugs market, 2014 - 2025 (USD Million)
5.5 Latin America
5.5.1 Latin America osteoporosis drugs market, 2014 - 2025 (USD Million)
5.5.2 Brazil
5.5.2.1 Brazil osteoporosis drugs market, 2014 - 2025 (USD Million)
5.5.3 Mexico
5.5.3.1 Mexico osteoporosis drugs market, 2014 - 2025 (USD Million)
5.6 MEA
5.6.1 MEA osteoporosis drugs market, 2014 - 2025 (USD Million)
5.6.2 South Africa
5.6.2.1 South Africa osteoporosis drugs market, 2014 - 2025 (USD Million)

6 Competitive Landscape
6.1 Strategy framework
6.2 Market participation categorization
6.3 Company Profiles
6.3.1 Pfizer, Inc.
6.3.1.1 Company overview
6.3.1.2 Financial performance
6.3.1.3 Geographic Foothold
6.3.1.4 Product benchmarking
6.3.1.5 Strategic initiatives
6.3.2 F.Hoffmann La Roche
6.3.2.1 Company overview
6.3.2.2 Financial performance
6.3.2.3 Geographic Foothold
6.3.2.4 Product benchmarking
6.3.2.5 Strategic initiatives
6.3.3 Teva Pharmaceuticals
6.3.3.1 Company overview
6.3.3.2 Financial performance
6.3.3.3 Geographic Foothold
6.3.3.4 Product benchmarking
6.3.4 Novartis AG
6.3.4.1 Company overview
6.3.4.2 Financial performance
6.3.4.3 Geographic Foothold
6.3.4.4 Product benchmarking
6.3.4.5 Strategic initiatives
6.3.5 Merck & Co AG
6.3.5.1 Company overview
6.3.5.2 Financial Performance
6.3.5.3 Geographic Foothold
6.3.5.4 Product benchmarking
6.3.5.5 Strategic initiatives
6.3.6 Amgen, Inc.
6.3.6.1 Company overview
6.3.6.2 Financial performance
6.3.6.3 Geographic Foothold
6.3.6.4 Product benchmarking
6.3.6.5 Strategic initiatives
6.3.7 Allergan plc
6.3.7.1 Company overview
6.3.7.2 Financial performance
6.3.7.3 Geographic Foothold
6.3.7.4 Product benchmarking
6.3.7.5 Strategic initiatives
6.3.8 GlaxoSmithKline
6.3.8.1 Company overview
6.3.8.2 Financial performance
6.3.8.3 Geographic Foothold
6.3.8.4 Product benchmarking
6.3.8.5 Strategic initiatives
6.3.9 Eli Lilly and Company
6.3.9.1 Company overview
6.3.9.2 Financial performance
6.3.9.3 Geographic Foothold
6.3.9.4 Product Benchmarking
6.3.9.5 Strategic initiatives

List of Tables

Table 1 North America osteoporosis drugs market, by product, 2014 - 2025 (USD Million)
Table 2 U.S. osteoporosis drugs market, by product, 2014 - 2025 (USD Million)
Table 3 Canada osteoporosis drugs market, by product, 2014 - 2025 (USD Million)
Table 4 Europe osteoporosis drugs market, by product, 2014 - 2025 (USD Million)
Table 5 UK osteoporosis drugs market, by product, 2014 - 2025 (USD Million)
Table 6 Germany osteoporosis drugs market, by product, 2014 - 2025 (USD Million)
Table 7 Asia Pacific osteoporosis drugs market, by product, 2014 - 2025 (USD Million)
Table 8 Japan osteoporosis drugs market, by product, 2014 - 2025 (USD Million)
Table 9 China osteoporosis drugs market, by product, 2014 - 2025 (USD Million)
Table 10 India osteoporosis drugs market, by product, 2014 - 2025 (USD Million)
Table 11 Latin America osteoporosis drugs market, by product, 2014 - 2025 (USD Million)
Table 12 Brazil osteoporosis drugs market, by product, 2014 - 2025 (USD Million)
Table 13 Mexico osteoporosis drugs market, by product, 2014 - 2025 (USD Million)
Table 14 MEA osteoporosis drugs market, by product, 2014 - 2025 (USD Million)
Table 15 South Africa osteoporosis drugs market, by product, 2014 - 2025 (USD Million)

List of Figures

Figure 1 Market summary
Figure 2 Market trends & outlook
Figure 3 Market segmentation & scope
Figure 4 Market driver relevance analysis (Current & future impact)
Figure 5 Market restraint relevance analysis (Current & future impact)
Figure 6 Penetration & Growth Prospect Mapping
Figure 7 Osteoporosis Drugs SWOT Analysis
Figure 8 Porter’s Five Forces Analysis
Figure 9 Porter’s Five Forces Analysis
Figure 10 Company Market Share,2015
Figure 11 Osteoporosis drugs market product outlook key takeaways
Figure 12 Osteoporosis drugs market: Type movement analysis
Figure 13 Branded market, 2014 - 2025 (USD Million)
Figure 14 Bisphosphonates market, 2014 - 2025 (USD Million)
Figure 15 Parathyroid hormone therapy market, 2014 - 2025 (USD Million)
Figure 16 Calcitonin market, 2014 - 2025 (USD Million)
Figure 17 SERM market, 2014 - 2025 (USD Million)
Figure 18 Rank ligand Inhibitors market, 2014 - 2025 (USD Million)
Figure 19 Others market, 2014 - 2025 (USD Million)
Figure 20 Generic market, 2014 - 2025 (USD Million)
Figure 21 Regional market place: Key takeaways
Figure 22 Regional outlook, 2015 & 2025
Figure 23 North America osteoporosis drugs market, 2014 - 2025 (USD Million)
Figure 24 U.S. osteoporosis drugs market, 2014 - 2025 (USD Million)
Figure 25 Canada osteoporosis drugs market, 2014 - 2025 (USD Million)
Figure 26 Europe osteoporosis drugs market, 2014 - 2025 (USD Million)
Figure 27 UK osteoporosis drugs market, 2014 - 2025 (USD Million)
Figure 28 Germany osteoporosis drugs market, 2014 - 2025 (USD Million)
Figure 29 Asia Pacific osteoporosis drugs market, 2014 - 2025 (USD Million)
Figure 30 Japan osteoporosis drugs market, 2014 - 2025 (USD Million)
Figure 31 China osteoporosis drugs market, 2014 - 2025 (USD Million)
Figure 32 India osteoporosis drugs market, 2014 - 2025 (USD Million)
Figure 33 Latin America osteoporosis drugs market, 2014 - 2025 (USD Million)
Figure 34 Brazil osteoporosis drugs market, 2014 - 2025 (USD Million)
Figure 35 Mexico osteoporosis drugs market, 2014 - 2025 (USD Million)
Figure 36 MEA osteoporosis drugs market, 2014 - 2025 (USD Million)
Figure 37 South Africa osteoporosis drugs market, 2014 - 2025 (USD Million)
Figure 38 Strategy framework
Figure 39 Participant categorization
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Pfizer, Inc.
  • F.Hoffmann La Roche
  • Teva Pharmaceuticals
  • Novartis AG
  • Merck & Co AG
  • Amgen, Inc.
  • Allergan plc
  • GlaxoSmithKline
  • Eli Lilly and Company
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll